Öppna denna publikation i ny flik eller fönster >>Visa övriga...
2013 (Engelska)Ingår i: Cellular Microbiology, ISSN 1462-5814, E-ISSN 1462-5822, Vol. 15, nr 7, s. 1088-1110Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
Type III secretion enables bacteria to intoxicate eukaryotic cells with anti-host effectors. A class of secreted cargo are the two hydrophobic translocators that form a translocon pore in the host cell plasma membrane through which the translocated effectors may gain cellular entry. In pathogenic Yersinia, YopB and YopD shape this translocon pore. Here, four in cis yopD mutations were constructed to disrupt a predicted α-helix motif at the C-terminus. Mutants YopD(I262P) and YopD(K267P) poorly localized Yop effectors into target eukaryotic cells and failed to resist uptake and killing by immune cells. These defects were due to deficiencies in host-membrane insertion of the YopD-YopB translocon. Mutants YopD(A263P) and YopD(A270P) had no measurable in vitro translocation defect, even though they formed smaller translocon pores in erythrocyte membranes. Despite this, all four mutants were attenuated in a mouse infection model. Hence, YopD variants have been generated that can spawn translocons capable of targeting effectors in vitro, yet were bereft of any lethal effect in vivo. Therefore, Yop translocators may possess other in vivo functions that extend beyond being a portal for effector delivery into host cells.
Ort, förlag, år, upplaga, sidor
Wiley-Blackwell, 2013
Nyckelord
virulence, coiled-coil, effector delivery, pore formation, regulation, YopD
Nationell ämneskategori
Mikrobiologi Biokemi Molekylärbiologi Mikrobiologi inom det medicinska området
Forskningsämne
infektionssjukdomar; mikrobiologi; molekylärbiologi
Identifikatorer
urn:nbn:se:umu:diva-67117 (URN)10.1111/cmi.12100 (DOI)000320394800004 ()2-s2.0-84879204564 (Scopus ID)
Forskningsfinansiär
Vetenskapsrådet
Anmärkning
This work, performed within the framework of the Umea Centre for Microbial Research-Linnaeus Program, was supported by grants from the Carl Tryggers Foundation for Scientific Research (M. S. F.), Swedish Research Council (H.W.-W., M. F., T. E., M. S. F.), Foundation for Medical Research at Umea University (M. S. F.) and J C Kempe Memorial Fund (T. R. C., A. A. A.).
2013-03-132013-03-132025-02-20Bibliografiskt granskad